Related Experiment Video
Updated: Feb 19, 2026
Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
Published on: January 7, 2019
Historical Perspective of Defining Charcot-Marie-Tooth Type 1B
1Veteran's Administration Puget Sound Health Care System, 1660 South Columbia Way, University of Washington Medical School, Seattle, Washington 98108, USA.
Insights
This study traces the genetic discovery of Charcot-Marie-Tooth disease type 1B (CMT1B). Researchers identified a mutation in the myelin P0 gene, providing a molecular basis for this neurogenetic disorder.
Area of Science:
- Neurogenetics
- Clinical Genetics
- Molecular Biology
Background:
- Charcot-Marie-Tooth disease (CMT) is a group of inherited peripheral neuropathies.
- A specific family (1521) with CMT, initially termed peroneal muscular atrophy, was studied for 36 years.
- Early studies noted severely slowed motor nerve conduction velocities (5-15 m/sec) in affected individuals.
Purpose of the Study:
- To detail the historical genetic linkage and molecular characterization of a subtype of CMT.
- To establish the molecular basis for Charcot-Marie-Tooth disease type 1B (CMT1B).
Main Methods:
- Longitudinal clinical follow-up of a single family over 36 years.
- Genetic linkage studies to identify chromosomal locations associated with CMT.
- Molecular analysis to pinpoint specific gene mutations responsible for the disorder.
Main Results:
- In 1980, linkage of CMT to the Duffy (Fy) locus on chromosome 1q was established in the family.
- This linkage was confirmed in another family, leading to the designation of this subtype as CMT1B.
- In 1993, a point mutation (Asp 90 Glu) in the myelin P0 gene was identified as the cause of CMT1B.
Conclusions:
- The identification of the myelin P0 gene mutation provided the molecular basis for CMT1B.
- This research highlights the evolution of neurogenetic disorder definition from linkage studies to molecular genetics.
- The study offers insights into the progression of clinical genetics over three decades.
Abstract:
A single family (1521) with CMT has been followed for 36 years (1962-1998) at Children's Hospital and the University of Washington in Seattle. The family was initially called peroneal muscular atrophy with severely slowed motor nerve conduction velocities (5-15 m/sec). In the late 1970s the family was part of several genetic studies of CMT and in 1980 represented linkage of CMT to the Duffy (Fy) locus on chromosome 1q. This finding was confirmed in an Indiana CMT family by Stebbins and Conneally (1982). This subtype of CMT was designated 1B. These investgations represented some of the last successful linkage studies in the now seemingly "ancient" pre-DNA marker era. In 1993 Hayasaka and colleagues found a point mutation in the myelin P0 gene (Asp 90 Glu) in this family, giving CMT1B a molecular basis. The historical development of this "defining" of a neurogenetic disorder reveals interesting insights into the workings of clinical genetics over the past 3 decades.
Related Concept Videos
01:35Pedigree Analysis
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:30Peripheral Artery Disease I: Introduction
01:30Atherosclerosis I: Introduction
02:59Animal Mitochondrial Genetics
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation